A Clinical Study to Evaluate the Safety and Efficacy of fixed dose combination of L-Ornithine-L-Aspartate 150 mg, Pancreatin IP 100mg enteric coated tablets as supportive and maintenance therapy in hepatitis

Phase 4

Conditions: Health Condition 1: K768- Other specified diseases of liver

Registration Number: CTRI/2022/06/043453

Lead Sponsor: Win Medicare Pvt Ltd

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Open to Recruitment

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1.Male/Female patients aged between 18-70 years with a clinical diagnosis of Hepatitis. The definition of Hepatitis is as mentioned below:

Hepatitis is a term to describe inflammation (Swelling) in the liver. It can be caused due to viral infection or when liver is exposed to harmful substances such as alcohol. Hepatitis may occur with limited or no symptoms, but often leads to jaundice, anorexia (poor appetite) and malaise. Hepatitis is of two types: Acute and Chronic.

2.Willingness to comply with the study schedule and procedures.

3.Patient willing to give written informed consent prior to screening.

Exclusion Criteria

1.Subject not willing to give written informed consent

2.Severe renal insufficiency (A serum creatinine value over 1.5 mg/100 ml)

3.Known hypersensitivity to any ingredient of the study drug.

4.Acute or chronic liver failure

5.Severe sepsis

6.Advanced cardiac or pulmonary disease

7.Neurologic disease (including head injury and drug intoxication).

8.Pregnancy and Lactation.

9.Female Subject not ready to use contraceptive measures during the trial period

10.Subject with any condition which in opinion of the investigator makes the him/her unsuitable for inclusion.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.Incidence, intensity, and causal relationship to labelled and un-labelled adverse reaction during the study period (Post screening after drug administration) <br/ ><br>2.Incidence, intensity, and causal relationship to Serious Adverse Events (SAEs) during the entire study period (Post screening after drug administration)Timepoint: Day 0 to Day 14

Secondary Outcome Measures

Name	Time	Method
Improvement in laboratory parameters SGOT, SGPT, Alkaline Phosphatase, Serum Ammonia, Serum Bilirubin at the day 0, day 7 and day 14 of the treatment. <br/ ><br> <br/ ><br>Physicians assessment in improvement according to a modified version of the Clinical Global Impression-Improvement (CGI-I) scale. <br/ ><br>Timepoint: Day-0, Day-07 & Day-14